Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.
作者信息
Cunha Burke A
出版信息
J Clin Microbiol. 2009 May;47(5):1613. doi: 10.1128/JCM.00404-09.
Abstract
摘要
相似文献
1
Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.
J Clin Microbiol. 2009 May;47(5):1613. doi: 10.1128/JCM.00404-09.
2
Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram-Negative Organisms?
Microb Drug Resist. 2017 Jun;23(4):437-446. doi: 10.1089/mdr.2016.0043. Epub 2016 Aug 26.
3
Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumonia in a systemic Septicaemia infection mouse model.
Mar Drugs. 2015 Apr 14;13(4):2287-305. doi: 10.3390/md13042287.
4
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249.
5
Successful treatment of postoperative multidrug-resistant Acinetobacter baumannii meningitis by tigecycline.
J Glob Antimicrob Resist. 2016 Jun;5:62-3. doi: 10.1016/j.jgar.2015.12.003. Epub 2015 Dec 21.
6
Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis.
Int J Infect Dis. 2010 Sep;14 Suppl 3:e224-6. doi: 10.1016/j.ijid.2009.07.022. Epub 2009 Dec 3.
7
Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.
J Antimicrob Chemother. 2010 Jun;65(6):1311-2. doi: 10.1093/jac/dkq116. Epub 2010 Apr 8.
8
In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
J Antibiot (Tokyo). 2013 Dec;66(12):705-8. doi: 10.1038/ja.2013.84. Epub 2013 Aug 28.
9
Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.
Int J Antimicrob Agents. 2016 Feb;47(2):107-16. doi: 10.1016/j.ijantimicag.2015.11.011. Epub 2015 Dec 13.
10
Genome sequences of two multidrug-resistant Acinetobacter baumannii strains isolated from a patient before and after treatment with tigecycline.
J Bacteriol. 2012 Dec;194(24):6979-80. doi: 10.1128/JB.01887-12.
引用本文的文献
1
Current and Emerging Treatment Options for Multidrug Resistant Urosepsis: A Review.
Antibiotics (Basel). 2022 Dec 15;11(12):1821. doi: 10.3390/antibiotics11121821.
2
Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis.
Medicine (Baltimore). 2020 Mar;99(10):e19466. doi: 10.1097/MD.0000000000019466.
3
Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.
Medicine (Baltimore). 2018 Sep;97(38):e12467. doi: 10.1097/MD.0000000000012467.
4
Acinetobacter Prosthetic Joint Infection Treated with Debridement and High-Dose Tigecycline.
Infect Chemother. 2016 Dec;48(4):324-329. doi: 10.3947/ic.2016.48.4.324. Epub 2016 Nov 8.
5
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections.
Open Forum Infect Dis. 2015 May 5;2(2):ofv050. doi: 10.1093/ofid/ofv050. eCollection 2015 Apr.
6
Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumonia in a systemic Septicaemia infection mouse model.
Mar Drugs. 2015 Apr 14;13(4):2287-305. doi: 10.3390/md13042287.
7
Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.
J Clin Microbiol. 2015 Apr;53(4):1286-93. doi: 10.1128/JCM.03184-14. Epub 2015 Feb 4.
8
Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
Crit Care. 2014 Jun 27;18(3):229. doi: 10.1186/cc13949.
9
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.
Crit Care. 2014 May 5;18(3):R90. doi: 10.1186/cc13858.
10
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.
Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.
本文引用的文献
1
In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect.
J Chemother. 2008 Oct;20(5):577-80. doi: 10.1179/joc.2008.20.5.577.
2
Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.
J Clin Microbiol. 2008 May;46(5):1892-3. doi: 10.1128/JCM.02494-07.
3
Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection.
J Chemother. 2007 Dec;19(6):753-4. doi: 10.1179/joc.2007.19.6.753.
4
Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit.
J Antimicrob Chemother. 2008 Mar;61(3):729-33. doi: 10.1093/jac/dkm541. Epub 2008 Jan 25.
5
Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
J Clin Microbiol. 2008 Feb;46(2):817-20. doi: 10.1128/JCM.01340-07. Epub 2007 Dec 12.
6
Tigecycline: a novel broad-spectrum antimicrobial.
Ann Pharmacother. 2007 Jun;41(6):965-72. doi: 10.1345/aph.1H543. Epub 2007 May 22.
7
Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias.
J Chemother. 2007 Apr;19(2):232-3. doi: 10.1179/joc.2007.19.2.232.
8
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.
J Antimicrob Chemother. 2006 Dec;58(6):1221-9. doi: 10.1093/jac/dkl403. Epub 2006 Sep 29.
9
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.
J Antimicrob Chemother. 2006 Aug;58(2):256-65. doi: 10.1093/jac/dkl224. Epub 2006 Jul 1.
10
Pharmacodynamics of doxycycline.
Clin Microbiol Infect. 2000 May;6(5):270-3. doi: 10.1046/j.1469-0691.2000.00058-2.x.
Zotero 插件